ArticleInsights into imaging2025
Prostate cancer detection with transrectal in-bore MRI biopsies: impact of prostate volume and lesion features.
Article in Insights into imaging, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Comparison of MRI-guided in-bore and fusion biopsy for small PI-RADS 4 prostate lesions.World journal of urology · 2026Article
- Transgluteal MRI in-bore prostate biopsy in routine clinical practice: a contemporary-cohort-study from a german tertiary center.International urology and nephrology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo systematically analyze the diagnostic outcome of transrectal in-bore MRI-guided biopsies as a function of prostate volume and lesion features.
methodsThis single-center study retrospectively included 184 consecutive patients with transrectal in-bore MRI biopsies and histological analysis after multiparametric MRI diagnostics of at least one PI-RADS ≥ 3 lesion. Diagnostic and biopsy MRI data were analyzed for a number of patient and imaging features, specifically prostate volume, lesion size, lesion location (longitudinal, sagittal and segmental) and lesion depth. Features were then compared for statistically significant differences in the cancer detection rate (CDR) of clinically significant (cs-PCa) and any prostate cancer (any-PCa) using categorical and continuous variables.
resultsA total of 201 lesions were biopsied detecting cs-PCa in 26% and any-PCa in 68%, respectively. In subgroup analyses of all features, the CDR of cs-PCa differed significantly between ranges of lesion size only (p < 0.001, largest for large lesions). In multivariable analysis, however, only PI-RADS score and PSA showed a significant association with a higher risk of cs-PCa.
conclusionsThe cancer detection rates of transrectal in-bore MRI-guided biopsies did not vary significantly for prostate volume, lesion size or lesion location. This suggests that the diagnostic performance of such an approach is not necessarily compromised for challenging biopsy settings like large glands, small lesions or eccentric locations. A translation of these findings to other cohorts might be limited by the low detection rate for clinically significant cancer. CRITICAL RELEVANCE STATEMENT: This systematic analysis indicates that the diagnostic performance of transrectal in-bore biopsies might not be substantially impaired by patient-specific factors like prostate volume, lesion size, and lesion location, making it a viable option for challenging biopsy cases as well. KEY POINTS: The impact of prostate and lesion features on in-bore MRI biopsy performance is controversial. Neither prostate volume, lesion size, nor location showed significant impact on cancer detection. In-bore biopsy does not seem to be limited by challenging sampling geometries.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.